Gastroenterology · Crohn's DiseaseTrial Updateclinicalmid-term

Phase II Trial Comparing IOUS-Guided Margin Selection in Crohn's Disease Surgery

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:04:52 AM

Assessment confidence: 80% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

This Phase II trial could redefine surgical standards for Crohn's disease, potentially enhancing patient outcomes and influencing competitive practices. The results may position the Cleveland Clinic as a leader in innovative surgical techniques, impacting market dynamics in gastroenterology. Regulatory context from MHRA (Semaglutide (Wegovy) approved to treat form of liver disease) supports the near-term read. Assessment grounded in 20 ranked evidence items (17 high-relevance).

Strategic Assessment

If successful, this approach may lead to improved surgical outcomes and could position the Cleveland Clinic as a leader in innovative surgical techniques for Crohn's disease. The strongest clinical anchor is Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD (ClinicalTrials.gov), moderate corpus alignment. In Gastroenterology · Crohn's Disease, 6 regulatory and 2 competitive items passed relevance filtering for Crohn's Disease surgical practices.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis. This trial could influence surgical practices and standards of care in Crohn's disease management, potentially impacting competing surgical techniques and technologies.

Regulatory Outlook

Regulatory risk is concentrated around Semaglutide (Wegovy) approved to treat form of liver disease (MHRA). Moderate corpus alignment. Relevant agencies in corpus: MHRA, FDA. As this is a clinical trial update, immediate regulatory implications are minimal, but successful outcomes could eventually influence future guidelines.

Key Opportunities

Improved surgical outcomes could enhance the Cleveland Clinic's reputation, potentially attracting more patients and influencing market share in gastroenterology services.
Upside for Crohn's Disease surgical practices may improve if Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Crohn's Disease surgical practices may improve if Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (ClinicalTrials.gov) delivers favorable follow-through.
If successful, this approach may lead to improved surgical outcomes and could position the Cleveland Clinic as a leader in innovative surgical techniques for Crohn's disease.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any subsequent changes in clinical guidelines or practices related to Crohn's disease surgery.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Semaglutide (Wegovy) approved to treat form of liver disease
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Drug Trials Snapshots: PALSONIFY
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparing Ultrasonic and Conventional Spirometry in Chronic Respiratory Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Immunogenicity and safety of an investigational quadrivalent measles, mumps, rubella, and varicella vaccine in children aged 4-6 years: A phase II, randomized, multi-country trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Crohn's Disease surgical practices
surgical technology companies

Commercial impact

medium

Improved surgical outcomes could enhance the Cleveland Clinic's reputation, potentially attracting more patients and influencing market share in gastroenterology services.

Regulatory impact

low

As this is a clinical trial update, immediate regulatory implications are minimal, but successful outcomes could eventually influence future guidelines.

What to watch

Monitor trial results and any subsequent changes in clinical guidelines or practices related to Crohn's disease surgery.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.